New hope for Tough-to-Treat T-Cell lymphoma: experimental therapy MB-105 enters phase 2
Disease control
Recruiting now
This study tests an experimental drug called MB-105 in about 46 adults with a specific type of T-cell lymphoma (CD5-positive) that has returned or not responded to standard treatments. The goal is to see if the drug can shrink or control the cancer and to check for side effects. …
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated May 11, 2026 02:34 UTC